Kuehn, Mareike; Wypyrsczyk, Lena; Stoessel, Sandra et al.
Physical Activity as a Treatment for Cancer-Related Fatigue in Children, Adolescents and Young Adults: A Systematic ReviewONCOLOGY RESEARCH AND TREATMENT. Bd. 47. 2024 S. 209-209
Zimmer, Philipp; Esser, Tobias; Lueftner, Diana et al.
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<SUP>+</SUP> breast cancerBMC MEDICINE. Bd. 22. H. 1. 2024
Frankenbach, Luisa Maria; Holler, Anne-Sophie; von Sochaczewski, Christina Oetzmann et al.
Physical Activity Levels in Children with Esophageal Atresia and Congenital Heart Disease: A Comparative Multicenter StudyEUROPEAN JOURNAL OF PEDIATRIC SURGERY. Bd. 35. H. 03. 2024 S. 171-179
Linxweiler, Helen; Thiesen, Judith; Kraemer, Irene
Physicochemical Stability of Nab-Paclitaxel (Pazenir) Infusion Dispersions in Original Glass Vials and EVA Infusion BagsPHARMACEUTICS. Bd. 16. H. 11. 2024
Almasi, Jannik; Thiesen, Judith; Kraemer, Irene
Physicochemical stability of ready-to-administer mitomycin C solutions for intravesical instillationEUROPEAN JOURNAL OF HOSPITAL PHARMACY. Bd. 31. H. 6. 2024 S. 571-576
Gericke, Adrian; Buonfiglio, Francesco
Physiological and Pathophysiological Relevance of Nitric Oxide Synthases (NOS) in Retinal Blood VesselsFRONTIERS IN BIOSCIENCE-LANDMARK. Bd. 29. H. 5. 2024
Hansen, Gesine; Zepp, Fred; Kerbl, Reinhold et al.
Pitfalls in pediatric and adolescent medicineMONATSSCHRIFT KINDERHEILKUNDE. Bd. 172. H. 12. 2024 S. 1042-1044
Hoffmann, Christian; Staatz, Gundula
Pitfalls in pediatric ultrasound diagnostics-Caution, danger of confusionMONATSSCHRIFT KINDERHEILKUNDE. Bd. 172. H. 12. 2024 S. 1078-1084
Grass, Albert; Kasajima, Atsuko; Foersch, Sebastian et al.
PITX2 as a Sensitive and Specific Marker of Midgut Neuroendocrine Tumors: Results from a Cohort of 1157 Primary Neuroendocrine NeoplasmsMODERN PATHOLOGY. Bd. 37. H. 4. 2024
Leypoldt, Lisa B.; Tichy, Diana; Besemer, Britta et al.
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myelomaFUTURE ONCOLOGY. 2024